Nerviano, Italy
Nerviano, Italy

Time filter

Source Type

News Article | November 29, 2016
Site: www.prweb.com

Goliath Technologies, the leading provider of proactive IT operations solutions for hybrid virtual server, virtual desktop, and cloud environments, has been selected by Accelera Solutions to support their cloud-based application availability testing service, Accelera Inspect, powered by Goliath Technologies. “We wanted to add a proactive, automated, cloud-based monitoring service to our current portfolio of cloud solutions. Our objective was to provide our customers with the capability to confirm that Citrix delivered applications will launch reliably every day, before end users even get to work,” said Sudhir Verma, VP of Cloud and Virtualization at Accelera Solutions. “Our decision to partner with Goliath Technologies was based on their unique ability to provide technology that supports all the areas of the service that we knew were critical. We’ve seen that they fully understand the business of managed service providers like ourselves, so we have great confidence in their ability to support us long term.” Goliath Technologies is the only proactive IT performance monitoring software for service providers that fully correlates the performance of the application delivery infrastructure with end user experience so that potential issues can be detected before end users are impacted. In addition, there is specific functionality for service providers including native multi-tenancy, role-based security, as well as grouping based on geography, application, infrastructure, and/or functional responsibility. See the Accelera story here. “We are very pleased that Accelera Solutions has selected Goliath Technologies to support their Cloud-based managed services offering, Accelera Inspect. We have made significant investments in functionality to support Service Providers and it is rewarding to see Accelera, MTM, Forthright, CSC, CDK Global, Atos and others opting for Goliath Technologies over other alternatives,” said Thomas Charlton, Chairman and CEO of Goliath Technologies. Goliath Technologies/Accelera Webinar – Tuesday, December 6th at 12:30pm ET To kick off our partnership and educate the market about the unique capabilities of this new service offering, we’ll be holding a joint webinar – live from the Accelera data center to demo how this service can benefit your IT operations. You can register here to see a live demo of the Application Testing & Availability Service! About Goliath Technologies Goliath Technologies provides proactive IT Operations software for IT organizations that address the evolving challenges of deploying virtual server and virtual desktop infrastructure whether on premise or in the cloud. Our solutions are purpose built for these emerging platforms and application delivery methods so they are vastly easier to use with greater functionality than alternative legacy products or point solutions. We communicate with existing enterprise frameworks, network centric solutions, and other IT management tools so we complement and extend existing IT investments with our virtual server and virtual desktop specific functionality. Customers include ADP, Facebook, UHS, Walmart, Bank of America, Office Depot, Wyndham Hotels, NASA, Thomson Reuters, and Xerox. About Accelera Solutions Accelera Solutions is a leading provider of cloud, mobility, and virtualization solutions, with a focus on end-user computing, cloud management, automation, and business continuity. Accelera’s customers include the Federal Government, DoD and civilian agencies, state and local Government, and commercial organizations throughout the United States. Services include professional consulting, staff augmentation, and full IT managed services. Headquartered in Fairfax, Virginia, Accelera maintains branch offices in Charleston, SC, San Antonio, TX, and Denver, CO.


FAIRFAX, Va., Nov. 14, 2016 /PRNewswire/ -- Accelera Solutions, Inc., an industry leader in Cloud, Mobility, and Virtualization solutions, announced today that Steven H. Weiss will be joining Accelera as the President and Chief Operating Officer.  Mr. Weiss will be supporting Accelera in i...


News Article | November 3, 2016
Site: www.marketwired.com

Accelera Solutions Elevated to Top Level of the New IGEL Partner Program FAIRFAX, VA and SAN FRANCISCO, CA--(Marketwired - Nov 3, 2016) - Accelera Solutions Inc., a leading provider of cloud, mobility, and virtualization solutions, and IGEL Technology, a world leader in the delivery of powerful workspace management software, IGEL™ Linux-powered thin clients, zero clients and all-in-one thin client solutions, today announced that Accelera Solutions has been named a Platinum member of the new IGEL Partner Program. The new distinction coincides with the release of IGEL's new Partner Program which has been designed to help channel partners capitalize on the thin client and workspace management software market to create new opportunities to grow their business more quickly and profitably. "We are pleased to recognize Accelera Solutions as a Platinum member of the IGEL partner ecosystem," said Jed Ayres, President and CEO, IGEL North America. "With an innovative approach to end-user computing, Accelera Solutions is a trusted advisor for organizations nationwide that want to optimize their endpoint infrastructure. Together we will help customers reduce power, hardware and administrative costs while simplifying endpoint security and control." Joe Brown, Accelera's President and COO, commented on the announcement, saying, "We're thrilled to be able to take our long-standing partnership with IGEL to the next level. This partnership reinforces our commitment to our customers to provide innovative solutions anchored by best-of-breed technology. Our relationship with IGEL continues to allow us to provide organizations with secure, high performance endpoint options that save cost, reduce administration and generally improve the way IT is being delivered." The newly enhanced IGEL Partner Program gives program members exclusive access to the resources that drive both hardware and software business, create new opportunities, fuel revenue growth and close deals faster. The new program's Platinum level gives members exclusive inclusion in the IGEL Platinum Partner Council, "first look" previews of IGEL NDA roadmaps, back end rebates, deal registration and protection and preferential disbursement of leads. Members also receive IGEL-delivered technical and sales enablement training, joint marketing support, and direct access to customer care, inside sales and support for technical inquiries. Program members additionally have access to beta programs for customers, and receive demo equipment and deep discounts for NFR equipment and licenses as well as the ability to increase margins based on tier partner levels and participation in deal registration. The new IGEL Partner Program launched on October 1, 2016. For more information on how to join, please visit: https://www.igel.com/us/resellers/become-an-authorized-partner.html. About Accelera Solutions Accelera Solutions is a leading provider of secure and flexible cloud, mobility, and virtualization solutions. Our areas of focus include end-user computing, desktop as a service, cloud management and automation, and business continuity. Our services include professional consulting, staff augmentation, and full IT managed services. Headquartered in Fairfax, Virginia, Accelera's customers include the Federal Government, DoD and civilian agencies, state and local Government, and commercial business throughout the United States. We maintain presence in Fairfax, VA, Charleston, SC, San Antonio, TX, and Denver, CO. About IGEL IGEL delivers powerful endpoint management software that is revolutionary in its simplicity and purpose-built for the enterprise. The company's world-leading products, including the IGEL Universal Management Suite, IGEL™ Linux-powered thin and zero clients, and all-in-one thin client solutions, deliver a smart and secure endpoint management experience that shifts granular control of thin and zero client devices from the end user to IT. This enables enterprises to remotely control all thin client devices from a single dashboard interface. With IGEL, IT teams can do more with less, lower their total cost of ownership and operation, and future-proof their organization. IGEL has 10 offices worldwide and is represented by partners in over 50 countries. For more information on IGEL, visit www.igel.com/us.


Beria I.,Nerviano Medical science Srl | Valsasina B.,Nerviano Medical science Srl | Brasca M.G.,Nerviano Medical science Srl | Ceccarelli W.,Nerviano Medical science Srl | And 14 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2010

A series of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives was optimized as Polo-like kinase 1 inhibitors. Extensive SAR afforded a highly potent and selective PLK1 compound. The compound showed good antiproliferative activity when tested in a panel of tumor cell lines with PLK1 related mechanism of action and with good in vivo antitumor efficacy in two xenograft models after iv administration. © 2010 Elsevier Ltd. All rights reserved.


Steimer J.-L.,Novartis | Dahl S.G.,University of Tromsø | De Alwis D.P.,Eli Lilly and Company | Gundert-Remy U.,Bundesinstitut For Risikobewertung | And 13 more authors.
European Journal of Cancer | Year: 2010

Physiologically based modelling of pharmacodynamics/toxicodynamics requires an a priori knowledge on the underlying mechanisms causing toxicity or causing the disease. In the context of cancer, the objective of the expert meeting was to discuss the molecular understanding of the disease, modelling approaches used so far to describe the process, preclinical models of cancer treatment and to evaluate modelling approaches developed based on improved knowledge. Molecular events in cancerogenesis can be detected using 'omics' technology, a tool applied in experimental carcinogenesis, but also for diagnostics and prognosis. The molecular understanding forms the basis for new drugs, for example targeting protein kinases specifically expressed in cancer. At present, empirical preclinical models of tumour growth are in great use as the development of physiological models is cost and resource intensive. Although a major challenge in PKPD modelling in oncology patients is the complexity of the system, based in part on preclinical models, successful models have been constructed describing the mechanism of action and providing a tool to establish levels of biomarker associated with efficacy and assisting in defining biologically effective dose range selection for first dose in man. To follow the concentration in the tumour compartment enables to link kinetics and dynamics. In order to obtain a reliable model of tumour growth dynamics and drug effects, specific aspects of the modelling of the concentration-effect relationship in cancer treatment that need to be accounted for include: the physiological/circadian rhythms of the cell cycle; the treatment with combinations and the need to optimally choose appropriate combinations of the multiple agents to study; and the schedule dependence of the response in the clinical situation. © 2009 Elsevier Ltd.


Degrassi A.,BU Oncology | Russo M.,BU Oncology | Nanni C.,Policlinico S. Orsola Malpighi | Patton V.,BU Oncology | And 6 more authors.
Molecular Cancer Therapeutics | Year: 2010

K-ras is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC), the most common form of lung cancer. Recent studies indicate that NSCLC patients with mutant K-ras do not respond to epidermal growth factor receptor inhibitors. In the attempt to find alternative therapeutic regimes for such patients, we tested PHA-848125, an oral pan cyclin-dependent kinase inhibitor currently under evaluation in phase II clinical trial, on a transgenic mouse model, K-RasG12DLA2, which develops pulmonary cancerous lesions reminiscent of human lung adenocarcinomas.We used magnetic resonance imaging and positron emission tomography to follow longitudinally disease progression and evaluate therapeutic efficacy in this model. Treatment of K-RasG12DLA2 mice with 40 mg/kg twice daily for 10 days with PHA-848125 induced a significant tumor growth inhibition at the end of treatment (P < 0.005) and this was accompanied by a reduction in the cell membrane turnover, as seen by 11C-Choline-positron emission tomography (P < 0.05). Magnetic resonance imaging data were validated versus histology and the mechanism of action of the compound was verified by immunohistochemistry, using cyclin-dependent kinase-related biomarkers phospho-Retinoblastoma and cyclin A. In this study, multimodality imaging was successfully used for the preclinical assessment of PHA-848125 therapeutic efficacy on a lung adenocarcinoma mouse model. This compound induced a volumetric and metabolic anticancer effect and could represent a valid therapeutic approach for NSCLC patients with mutant K-ras. ©2010 AACR.


The 3rd Global CRO Council Closed Forum was held on the 3rd and 4th July 2011 in Guildford, United Kingdom, in conjunction with the 19th International Reid Bioanalytical Forum. In attendance were 21 senior-level representatives from 19 CROs on behalf of nine European countries and, for many of the attendees, this occasion was the first time that they had participated in a GCC meeting. Therefore, this closed forum was an opportunity to increase awareness of the aim of the GCC and how it works, share information about bioanalytical regulations and audit findings from different agencies, their policies and procedures and also to discuss some topics of interest and aim to develop ideas and provide recommendations for bioanalytical practices at future GCC meetings in Europe.


Bertazzolo W.,Veterinary Animal Hospital Citta Of Pavia | Didier M.,Veterinary Animal Hospital Citta Of Pavia | Gelain M.E.,University of Padua | Rossi S.,Veterinary Institute of Novara | And 6 more authors.
Veterinary Clinical Pathology | Year: 2014

Background: The distinction between adrenocortical tumors and pheochromocytoma can be challenging using clinical findings, diagnostic imaging and laboratory tests. Cytology might be a simple, minimally invasive method to reach a correct diagnosis. Objectives: The purpose of this study was to assess the accuracy of cytology in differentiating cortical from medullary tumors of the adrenal glands in dogs and cats. Methods: Cytologic key features of adrenocortical tumors and pheochromocytoma were defined by one reference author. Cytologic specimens from primary adrenal tumors were submitted to 4 cytopathologists who were asked to classify the tumors based on the previously defined key features without knowledge of previous classification. Results: Twenty specimens from histologically confirmed adrenal tumors (Group 1) and 4 specimens from adrenal tumors causing adrenal-dependent Cushing's syndrome (Group 2) were evaluated by the 4 cytopathologists. Accuracy in differentiating cortical from medullary origin ranged from 90% to 100%, with a Kappa coefficient of agreement between cytopathologists of 0.95. Conclusions: The origin of an adrenal tumor can be easily determined by cytology alone in many cases. However, cytology was not reliable in distinguishing benign from malignant neoplasia. Additional studies are needed to assess possible risks and complications associated with fine-needle biopsy of adrenal tumors in dogs and cats. © 2014 American Society for Veterinary Clinical Pathology and European Society for Veterinary Clinical Pathology.


Cenacchi V.,Chiesi Farmaceutici Spa | Battaglia R.,Accelera | Cinato F.,Accelera | Riccardi B.,Chiesi Farmaceutici Spa | And 4 more authors.
Xenobiotica | Year: 2015

1. The metabolism of CHF 6001, a novel PDE4 inhibitor, was determined in vitro in mouse, rat, dog, monkey and human microsomes and hepatocytes and in vivo in plasma, urine, feces and bile of rats after intravenous and intratracheal administration. 2. The behavior of CHF 6001 in microsomes and hepatocytes changed across species. CYP3A4/5 isoenzymes were identified to be the primary enzymes responsible for the metabolism of CHF 6001 in human liver microsomes. 3. In the rat, CHF 6001 was found extensively metabolized in urine, feces and bile, but not in plasma, where CHF 6001 was the main compound present. The metabolite profiles were different in the four biological matrices from both qualitative and quantitative point of view. 4. CHF 6001 was metabolized through hydrolysis with the formation of the alcohol CHF 5956, loss of a chlorine atom, loss of the N-oxide, hydroxylation, loss of the cyclopropylmethyl group in the alcohol moiety, conjugation with glucuronic acid, glutathione and cysteine-glycine. 5. The major metabolite present in the bile was isolated and characterized by nuclear magnetic resonance analysis. It derived from CHF 6001 through contraction of the pyridine-N-oxide ring to N-hydroxy pyrrole and conjugation with glucuronic acid. © 2015 Informa UK Ltd. All rights reserved.


PubMed | Accelera
Type: Congresses | Journal: Bioanalysis | Year: 2011

The 3rd Global CRO Council Closed Forum was held on the 3rd and 4th July 2011 in Guildford, United Kingdom, in conjunction with the 19th International Reid Bioanalytical Forum. In attendance were 21 senior-level representatives from 19 CROs on behalf of nine European countries and, for many of the attendees, this occasion was the first time that they had participated in a GCC meeting. Therefore, this closed forum was an opportunity to increase awareness of the aim of the GCC and how it works, share information about bioanalytical regulations and audit findings from different agencies, their policies and procedures and also to discuss some topics of interest and aim to develop ideas and provide recommendations for bioanalytical practices at future GCC meetings in Europe.

Loading Accelera collaborators
Loading Accelera collaborators